Combining Adaptive Seamless Phase II/III Designs and Group Sequential Analysis for Time-to-Event Endpoints in Oncology Trials

Wentian Guo, Qingyu Chen, Chi Song +4

Seamless Phase II/III designs are a natural vehicle for the randomized dose optimization called for by the US Food and Drug Administration's Project Optimus initiative. Their exten…